Literature DB >> 17117067

MRI-negative, bone scintigram-positive in early osteonecrosis of the knees.

Bruce J M Warwick1, Vincent Caristo, Nathan Hartin, Wisam Ihsleish, Chandima Perera, Hans Van der Wall.   

Abstract

Nontraumatic avascular necrosis (AVN) of bone is a well-reported complication of glucocorticoid therapy for immunologic and malignant disease. We present the case of a 13-year-old girl with no history of trauma who presented with a 5-day history of increasing pain in both knees after cord blood transplantation for acute lymphoblastic leukemia. Plain film and magnetic resonance imaging (MRI) were reported as normal. Bone scintigraphy revealed evidence of bilateral avascular necrosis in the distal femora. MRI subsequently became abnormal several weeks later. The case illustrates the natural history of AVN, in which changes that are detected by MRI can take several weeks to develop. The scintigraphic findings influenced early management of the condition.

Entities:  

Mesh:

Year:  2006        PMID: 17117067     DOI: 10.1097/01.rlu.0000246890.17699.2a

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

Review 1.  Osteonecrosis in children after therapy for malignancy.

Authors:  Sue C Kaste; Evguenia J Karimova; Michael D Neel
Journal:  AJR Am J Roentgenol       Date:  2011-05       Impact factor: 3.959

Review 2.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

3.  On a case of multifocal osteonecrosis in a patient suffering from acute lymphoblastic leukemia.

Authors:  Giuseppe Solarino; Lorenzo Scialpi; Marco Bruno; Berenice De Cillis
Journal:  Chir Organi Mov       Date:  2008-05-12

4.  Skeletal scintigraphy manifestations of hematologic disorders.

Authors:  Shrikant V Solav; Ritu Bhandari; Pallavi Solav
Journal:  Indian J Nucl Med       Date:  2012-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.